Aberdeen Group
AZN icon

Aberdeen Group’s AstraZeneca AZN Stock Holding History

Aberdeen Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.2M Sell
327,978
-60,174
-16% -$11.3M 0.09% 188
2026
Q1 		$76.6M Sell
388,152
-32,635
-8% -$6.29M 0.12% 147
2025
Q4 		$77.4M Buy
420,787
+20,678
+5% +$3.63M 0.12% 140
2025
Q3 		$61.4M Buy
400,109
+2,317
+0.6% +$351K 0.1% 172
2025
Q2 		$55.6M Buy
397,792
+7,896
+2% +$1.11M 0.09% 188
2025
Q1 		$57.3M Sell
389,896
-310,849
-44% -$45M 0.11% 170
2024
Q4 		$91.8M Buy
700,745
+19,587
+3% +$2.74M 0.17% 123
2024
Q3 		$106M Sell
681,158
-72,104
-10% -$11.6M 0.19% 119
2024
Q2 		$117M Buy
753,262
+5,224
+0.7% +$786K 0.23% 101
2024
Q1 		$101M Buy
748,038
+37,600
+5% +$4.98M 0.2% 118
2023
Q4 		$95.7M Buy
710,438
+551,245
+346% +$71.7M 0.21% 112
2023
Q3 		$21.6M Buy
159,193
+800
+0.5% +$109K 0.06% 313
2023
Q2 		$22.7M Sell
158,393
-500
-0.3% -$73.6K 0.05% 318
2023
Q1 		$22.1M Buy
158,893
+10,450
+7% +$1.41M 0.06% 323
2022
Q4 		$20.1M Hold
148,443
– – 0.05% 331
2022
Q3 		$16.3M Hold
148,443
– – 0.05% 350
2022
Q2 		$19.6M Sell
148,443
-14,855
-9% -$1.95M 0.06% 291
2022
Q1 		$21.7M Sell
163,298
-19,400
-11% -$2.33M 0.06% 294
2021
Q4 		$21.3M Sell
182,698
-15,250
-8% -$1.79M 0.05% 328
2021
Q3 		$23.8M Buy
197,948
+12,320
+7% +$1.43M 0.05% 315
2021
Q2 		$22.2M Buy
185,628
+5,650
+3% +$620K 0.05% 338
2021
Q1 		$17.9M Buy
179,978
+600
+0.3% +$60.3K 0.04% 363
2020
Q4 		$17.9M Buy
179,378
+44,528
+33% +$4.72M 0.04% 343
2020
Q3 		$14.8M Sell
134,850
-900
-0.7% -$100K 0.04% 341
2020
Q2 		$14.4M Hold
135,750
– – 0.04% 345
2020
Q1 		$12.1M Buy
+135,750
New +$12.8M 0.04% 358

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Aberdeen Group's AZN Position: Q2 2026 in Review

Aberdeen Group reduced its AstraZeneca (AZN) stake by 16% in Q2 2026, selling an estimated $11.3M and leaving 327,978 shares worth $62.2M. The position accounts for 0.09% of the portfolio, ranked #188.

Aberdeen Group first reported a position in AZN in Q1 2020 and has held it in 26 quarters since. The position peaked at $117M in Q2 2024. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Aberdeen Group held 327,978 shares of AstraZeneca worth $62.2M as of Q2 2026.
  • Aberdeen Group sold 60,174 AstraZeneca shares in Q2 2026, an estimated $11.3M.
  • AstraZeneca made up 0.09% of Aberdeen Group's portfolio in Q2 2026, its #188 holding.
  • Aberdeen Group first reported a position in AstraZeneca in Q1 2020 and has held it in 26 quarters since.
  • Aberdeen Group's AstraZeneca position peaked at $117M in Q2 2024.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.